Literature DB >> 2479624

Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A, -B, and -C molecules.

B P Chen1, V Lam, E E Kraus, R DeMars, P M Sondel.   

Abstract

HLA-loss variants of an Epstein-Barr virus-transformed B-lymphoblastoid cell line (EBV-LCL) 721 were used as target cells to identify HLA molecules utilized by EBV-LCL-specific cytotoxic T cells. Split culture analysis of cytotoxic T cells plated at limiting dilution showed killing of HLA-loss variants bearing either HLA-A2 or -B5 molecules, with 10 times higher frequency of cytotoxic T cells restricted by the HLA-B5 molecule. Clonal analysis confirmed the restriction by HLA-A2 or -B5 of some cytotoxic T-cell clones and identified cytotoxic T-cell clones cytolytic for target cells which do not express HLA-A or -B but do express the HLA-C determinant. Thus, our results show immunodominance of the HLA-B5 restriction determinant for EBV-induced antigens in the donor of the HLA-loss variants and provide evidence that the HLA-C molecule can also serve as restriction determinant for EBV-LCL-specific cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479624     DOI: 10.1016/0198-8859(89)90099-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  9 in total

1.  Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.

Authors:  I Bourgault; A Gomez; E Gomard; J P Levy
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

2.  Different rates of HLA class I molecule assembly which are determined by amino acid sequence in the alpha 2 domain.

Authors:  A Hill; M Takiguchi; A McMichael
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 3.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  HLA-C revisited. Ten years of change.

Authors:  C S Falk; D J Schendel
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 5.  Molecular evolution of elements controlling HLA-C expression: Adaptation to a role as a killer-cell immunoglobulin-like receptor ligand regulating natural killer cell function.

Authors:  Stephen K Anderson
Journal:  HLA       Date:  2018-11       Impact factor: 4.513

6.  Allele-specific peptide ligand motifs of HLA-C molecules.

Authors:  K Falk; O Rötzschke; B Grahovac; D Schendel; S Stevanović; V Gnau; G Jung; J L Strominger; H G Rammensee
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

7.  Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone.

Authors:  R P Johnson; A Trocha; T M Buchanan; B D Walker
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C.

Authors:  J Zemmour; P Parham
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

9.  Patr-A and B, the orthologues of HLA-A and B, present hepatitis C virus epitopes to CD8+ cytotoxic T cells from two chronically infected chimpanzees.

Authors:  H Kowalski; A L Erickson; S Cooper; J D Domena; P Parham; C M Walker
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.